Project Grant R01CA290693
Award Date
12/11/24
Completion Date
11/30/29
Dollars Obligated
$612K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This federal Project Grant award of $459,747.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Wisconsin-Madison to define the effect of copy number amplification on the regulation of oncogenes in high-grade serous ovarian carcinoma. The research will examine the contributions of superenhancers at the 8q22 region, with the goal of advancing scientific understanding and potential treatment...
This federal Project Grant award, valued at $1,555,000.00 and provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, will fund research at the University of Wisconsin - Madison to develop population modeling approaches for optimizing equitable ovarian cancer outcomes. The research efforts aim to transform healthcare for military service members and the general public by advancing innovative and impactful biomedical...
This $2,073,138 Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), is focused on discovering a new class of tumor antigens and T-cell receptors (TCRs) targeting platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The primary awardee, the University of California, Los Angeles (UCLA), will leverage long-read RNA sequencing, immunopeptidomics, and computational epitope prediction to identify cancer-specific peptide...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to elucidate the spatiotemporal dynamics of the extracellular matrix (ECM) in response to platinum-based chemotherapy treatment in high-grade serous ovarian carcinoma (HGSC). The $584,081 award, effective May 12, 2025 through April 30, 2030, will enable Sanford Research, a non-profit biomedical research organization, to utilize innovative...
The National Cancer Institute (NCI) awarded a $506,309 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis). The grant, awarded on May 7, 2025, will fund a research project to investigate the mechanism by which ovarian cancer cells interact with their microenvironment to promote metastasis. Specifically, the research aims to determine how microenvironmental signals activate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of an engineered prodrug therapy that leverages tumor-associated proteases to selectively deliver potent cytotoxins to cancer cells. The proposed research aims to define the mechanisms of action of this novel anti-cancer strategy, and determine the efficacy, pharmacokinetics, and pharmacodynamics of combining this prodrug therapy with standard-of-care chemotherapy for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,373,308.00 to the University of Pittsburgh to conduct research on the role of acetylcarnitine metabolism in chemoresistance of high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, and 2) investigate whether interventions that...
This Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program will support research to investigate how changes in the pre-metastatic niche (PMN) facilitate breast cancer metastasis. The total award amount is $521,240 over the project period from Sep 1, 2024 to Aug 31, 2029. The research aims to identify critical events within the PMN that enable metastatic tumor cell colonization, promote phenotypic heterogeneity, and contribute to drug resistance....
This $577,680 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund research at the University of Colorado aimed at overcoming therapy-resistant ovarian cancer. The project, titled "Targeting EHMT1/2 to Overcome Therapy-Resistant Ovarian Cancer", will run from May 1, 2025 to April 30, 2029. The research seeks to develop innovative approaches to prevent, diagnose, and treat ovarian cancer, with a...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support research on the pharmacological potential of combined translation and autophagy inhibition in high-grade serous ovarian cancer (HGSOC). The $241,944 award, effective August 1, 2024 through July 31, 2026, will enable researchers at the University of Illinois to study the efficacy and mechanism of two natural product...